GP KFPs / SAQs · mental-health
First-episode psychosis — KFP-style written assessment
KFP-style staged scenarios on first-episode psychosis in general practice: recognising early warning signs and shortening DUP, excluding medical and substance mimics, initiating low-dose antipsychotics with metabolic monitoring, and structuring family psychoeducation.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
First-episode psychosis: detection, differentials, and the first prescription
KFP 1 (10 marks)
A 19-year-old apprentice has drifted apart from his mates over six months. His mother reports he has become suspicious, says workmates are "talking about him", stays up all night, and recently stopped his apprenticeship. She asks whether he is "just smoking too much weed" — he uses cannabis most days. [12] [23]
- Name the symptom clusters present and give one example from each. (3) [12]
- What is duration of untreated psychosis, and why does it matter for what you do today? (4) [2] [3]
- His mother wants to know if this is just cannabis. Answer her with evidence. (3) [23] [19]
Model answers
- Positive symptoms (persecutory ideation — beliefs that workmates talk about him), negative symptoms (social withdrawal, loss of connection with friends), and possibly disorganised/cognitive features (functional decline ending the apprenticeship). Naming the clusters frames the assessment and the referral letter. [12]
- DUP is the time from first persistent psychotic symptom to adequate treatment. Longer DUP associates with worse outcome at 6 and 12 months across symptoms, functioning and quality of life, independent of premorbid adjustment; shorter DUP predicts greater antipsychotic response. Pooled mean DUP is about 61 weeks with median near 12 weeks — so today's consultation either starts the clock properly or extends it. Refer to an early-intervention service now. [2] [3]
- Cannabis is neither the whole story nor irrelevant. Ever-use raises psychotic outcome risk (pooled OR 1.41), and daily high-potency use nearly five-fold (OR ~4.8). But primary psychoses arise without cannabis, and cannabis-induced psychosis itself relapses in 20% within two years (25.7% when cannabis-induced). The correct answer is assessment plus referral regardless of his use, and structured cannabis reduction as part of treatment. [23] [19]
References14ShowHide
- [2]Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry, 2005.PMID 16143729
- [3]Perkins DO, Gu H, Boteva K, Lieberman JA Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry, 2005.PMID 16199825
- [12]Boonstra N, Klaassen R, Sytema S, Marshall M, De Haan L, et al. Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. Schizophr Res, 2012.PMID 23025994
- [27]Mohamed MFH, Danjuma M, Mohammed M, Mohamed S, Siepmann M, et al. Myxedema Psychosis: Systematic Review and Pooled Analysis. Neuropsychiatr Dis Treat, 2021.PMID 34447249
- [41]Mengistu T, Subedi A, Unamba U, Khan SA, Mowoe E, et al. Anti-NMDA Receptor Encephalitis Presenting as Acute Psychosis. Clin Case Rep, 2026.PMID 41641166
- [23]Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry, 2019.PMID 30902669
- [19]Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry, 2016.PMID 27567467
- [33]Zhou T, Pu C, Huang Z, Gao T, Zhou E, et al. Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. Asian J Psychiatr, 2023.PMID 37094459
- [35]Carolan A, Hynes-Ryan C, Agarwal SM, Bourke R, Cullen W, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophr Bull, 2025.PMID 39657713
- [30]Rodolico A, Bighelli I, Avanzato C, Concerto C, Cutrufelli P, et al. Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry, 2022.PMID 35093198
- [43]Benazzi TA, Arturi VR, da Silva LHT, Baldez DP, Baroni G, Gama CS Optimizing Early Psychosis Care through Family Psychoeducation: A Systematic Review and Meta-Analysis. Braz J Psychiatry, 2026.PMID 42068331
- [38]Klau J, Gonzalez-Chica D, Raven M, Aboustate N, Jureidini J Cardiometabolic monitoring in children and adolescents prescribed antipsychotics in Australian primary care, 2011 to 2017. Aust N Z J Psychiatry, 2025.PMID 40801228
- [9]Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med, 2012.PMID 21846426
- [39]de Bruijn MAAM, Leypoldt F, Dalmau J, Lee ST, Honnorat J, et al. Autoimmune encephalitis. Nat Rev Dis Primers, 2025.PMID 40935848